» Articles » PMID: 35770984

Exploring HIV-Associated Neurocognitive Impairment in the Era of Effective Antiretroviral Therapy: A Primary Healthcare Perspective

Overview
Journal Qual Health Res
Publisher Sage Publications
Specialty Health Services
Date 2022 Jun 30
PMID 35770984
Authors
Affiliations
Soon will be listed here.
Abstract

The prevalence of HIV-associated neurocognitive impairment (H-NCI) is concerning. Individuals on effective antiretroviral therapy (ART) may still be at risk for H-NCI as they experience longer life expectancies. There are, however, few professionals with knowledge and skills to identify H-NCI, in low- and middle-income countries. We explored qualitatively, primary healthcare workers' knowledge and views of H-NCI, in the era of effective ART, particularly their views toward task-sharing of H-NCI screening from specialists to mid-level or lay healthcare providers. The first phase of data collection involved two focus group discussions (FGDs) 23 primary healthcare workers from two facilities in the Western Cape participated in the FGDs. In the second phase of data collection12 individual, in-depth interviews were conducted in KwaZulu-Natal. Using thematic analysis, several key themes emerged. Although healthcare providers were unable to specifically identify H-NCI, they described several HIV disease and treatment related or mental health comorbidities that could be responsible for the symptoms. Despite healthcare workers reporting low frequencies of H-NCI, they favoured receiving training to screen for H-NCI with a view toward providing holistic care.

Citing Articles

Screening for HIV-associated neurocognitive impairment: Development and validation of an abbreviated neuropsychological test battery for use in South African clinical settings.

Spies G, Deist M, Suliman S, Seedat S Neuropsychology. 2022; 37(2):166-180.

PMID: 36442008 PMC: 9992844. DOI: 10.1037/neu0000872.

References
1.
de Jager C, Joska J, Hoffman M, Borochowitz K, Combrinck M . Dementia in rural South Africa: A pressing need for epidemiological studies. S Afr Med J. 2015; 105(3):189-90. DOI: 10.7196/samj.8904. View

2.
Gouse H, Masson C, Henry M, Marcotte T, London L, Kew G . Assessing HIV provider knowledge, screening practices, and training needs for HIV-associated neurocognitive disorders. A short report. AIDS Care. 2020; 33(4):468-472. PMC: 7483165. DOI: 10.1080/09540121.2020.1736256. View

3.
Terpstra A, Worthington C, Ibanez-Carrasco F, OBrien K, Yamamoto A, Chan Carusone S . "I'm Just Forgetting and I Don't Know Why": Exploring How People Living With HIV-Associated Neurocognitive Disorder View, Manage, and Obtain Support for Their Cognitive Difficulties. Qual Health Res. 2018; 28(6):859-872. DOI: 10.1177/1049732318761364. View

4.
Heaton R, Franklin D, Ellis R, McCutchan J, Letendre S, LeBlanc S . HIV-associated neurocognitive disorders before and during the era of combination antiretroviral therapy: differences in rates, nature, and predictors. J Neurovirol. 2010; 17(1):3-16. PMC: 3032197. DOI: 10.1007/s13365-010-0006-1. View

5.
Valcour V, Sithinamsuwan P, Letendre S, Ances B . Pathogenesis of HIV in the central nervous system. Curr HIV/AIDS Rep. 2010; 8(1):54-61. PMC: 3035797. DOI: 10.1007/s11904-010-0070-4. View